Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/42367
Campo DC Valoridioma
dc.contributor.authorWägner, A. M.-
dc.contributor.authorMiranda Calderín, Guillermo-
dc.contributor.authorUgarte-Lopetegui, M. A.-
dc.contributor.authorMarrero-Santiago, H.-
dc.contributor.authorSuárez-Castellano, L.-
dc.contributor.authorLópez-Madrazo, M. J.-
dc.contributor.authorAlberiche-Ruano, M. P.-
dc.contributor.authorAbselam Ahmed, N.-
dc.contributor.authorAlemán, C.-
dc.contributor.authorCastellot-Martín, A.-
dc.contributor.authorDíez del Pino, A.-
dc.contributor.authorNóvoa-Mogollón, F. J.-
dc.date.accessioned2018-11-05T11:39:59Z-
dc.date.available2018-11-05T11:39:59Z-
dc.date.issued2019-
dc.identifier.issn1262-3636-
dc.identifier.otherWoS-
dc.identifier.urihttp://hdl.handle.net/10553/42367-
dc.description.abstractAims To assess the effect of the GLP-1 analogue liraglutide on measures of cardiac function and physical performance in patients with type 2 diabetes (T2D). Methods In this phase-IV randomized double-blind placebo-controlled parallel-group clinical trial at a tertiary hospital, T2D patients with HbA1c levels of 7–10% with oral agents and/or intermediate-/long-acting insulin were allocated (computer-generated randomization, ratio 1:1) to either liraglutide 1.8 mg/day or a placebo for 6 months. The primary endpoint was maximum oxygen consumption (VO2max) during cycle ergometry, while other procedures included a 6-min walk test, echocardiography, anthropometry and blood tests. Safety endpoints were also monitored, and an intention-to-treat analysis was performed. Results A total of 24 patients (15 women) aged 52 (11.7) years, with diabetes duration of 8.7 (5.8) years, BMI 34.98 (6.2) kg/m2 and HbA1c 8.2% (0.68%), were randomized to liraglutide 1.8 mg daily or placebo. There were no differences in VO2max [17.98 (4.8) vs. 15.90 (4.96) mL/kg/min; P > 0.10], VE/VCO2 slope [30.18 (4.8) vs. 32 (4.49)], left ventricular ejection fraction or 6-min walk test [530.7 (86) vs. 503.9 (84) m] at 6 months. HbA1c was lower (6.7% vs. 7.7%; P =  0.005), with a trend towards lower maximum systolic blood pressure during ergometry [171.7 (24.4) vs. 192.5 (25.6); P = 0.052] in the liraglutide group at the end of the study. There were no severe adverse events. Conclusion In this trial, liraglutide improved glycaemic control in T2D, but had no significant effects on either physical performance or myocardial function.-
dc.languageeng-
dc.publisher1262-3636-
dc.relation.ispartofDiabetes and Metabolism-
dc.sourceDiabetes & Metabolism[ISSN 1262-3636],v. 45 (3), p. 268-275, (Junio 2019)-
dc.subject32 Ciencias médicas-
dc.subject.otherDiabetes-
dc.subject.otherErgometry-
dc.subject.otherGLP-1 agonist-
dc.subject.otherMaximum oxygen consumption-
dc.subject.otherRandomized controlled trial-
dc.subject.otherVentricular function-
dc.titleEffect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2)-
dc.typeinfo:eu-repo/semantics/article-
dc.typeArticle-
dc.identifier.doi10.1016/j.diabet.2018.08.010-
dc.identifier.scopus85054016737-
dc.identifier.isi000473250400007-
dc.contributor.authorscopusid7401456520-
dc.contributor.authorscopusid6504769712-
dc.contributor.authorscopusid57190138377-
dc.contributor.authorscopusid55953726600-
dc.contributor.authorscopusid11940471400-
dc.contributor.authorscopusid26536142100-
dc.contributor.authorscopusid57190139526-
dc.contributor.authorscopusid57204000920-
dc.contributor.authorscopusid19638685500-
dc.contributor.authorscopusid57204000975-
dc.contributor.authorscopusid6506293404-
dc.contributor.authorscopusid57041246400-
dc.identifier.eissn1878-1780-
dc.description.lastpage275-
dc.identifier.issue3-
dc.description.firstpage268-
dc.relation.volume45-
dc.investigacionCiencias de la Salud-
dc.type2Artículo-
dc.contributor.daisngid450201-
dc.contributor.daisngid7989267-
dc.contributor.daisngid31217854-
dc.contributor.daisngid8309483-
dc.contributor.daisngid8504772-
dc.contributor.daisngid8554851-
dc.contributor.daisngid13615017-
dc.contributor.daisngid25043708-
dc.contributor.daisngid20091221-
dc.contributor.daisngid31109078-
dc.contributor.daisngid22058530-
dc.contributor.daisngid4992898-
dc.description.numberofpages8-
dc.utils.revision-
dc.contributor.wosstandardWOS:Wagner, AM-
dc.contributor.wosstandardWOS:Miranda-Calderin, G-
dc.contributor.wosstandardWOS:Ugarte-Lopetegui, MA-
dc.contributor.wosstandardWOS:Marrero-Santiago, H-
dc.contributor.wosstandardWOS:Suarez-Castellano, L-
dc.contributor.wosstandardWOS:Lopez-Madrazo, MJ-
dc.contributor.wosstandardWOS:Alberiche-Ruano, MP-
dc.contributor.wosstandardWOS:Ahmed, NA-
dc.contributor.wosstandardWOS:Aleman, C-
dc.contributor.wosstandardWOS:Castellot-Martin, A-
dc.contributor.wosstandardWOS:del Pino, AD-
dc.contributor.wosstandardWOS:Novoa-Mogollon, FJ-
dc.date.coverdateJunio 2019-
dc.identifier.ulpgces
dc.description.sjr1,429
dc.description.jcr4,731
dc.description.sjrqQ1
dc.description.jcrqQ1
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-7663-9308-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameWägner, Anna Maria Claudia-
crisitem.author.fullNameMiranda Calderín, Guillermo-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

17
actualizado el 17-nov-2024

Citas de WEB OF SCIENCETM
Citations

15
actualizado el 17-nov-2024

Visitas

172
actualizado el 12-oct-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.